NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, has announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors can access a live and archived webcast of the event at the provided link. Those interested in participating via telephone can dial +1-877-407-3982 and reference Conference ID 13749123. The webcast will be archived on the company's investor relations website for at least 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – NPCE
On the day this news was published, NPCE declined 1.67%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1690707&tp_key=080b652fbc. Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13749123. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will NeuroPace (NPCE) report its Q3 2024 financial results?
How can investors access NeuroPace's (NPCE) Q3 2024 earnings call?
What time is NeuroPace's (NPCE) Q3 2024 earnings conference call?
Where can I find the archived webcast of NeuroPace's (NPCE) Q3 2024 earnings call?
